Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Evra
EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch · Abschnitt 4.3 · PDF-Seite 5–6
HOS-110299 · Präparat HOS-093363
5
• Presence or risk of arterial thromboembolism (ATE)
• Arterial thromboembolism – current arterial thromboembolism, history of arterial
thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina
pectoris);
• Cerebrovascular disease – current stroke, history of stroke or prodromal condition
(e.g. transient ischaemic attack, TIA);
• Known hereditary or acquired predisposition for arterial thromboembolism, such as
hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies,
lupus anticoagulant);
• History of migraine with focal neurological symptoms;
• A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or
to the presence of one serious risk factor such as:
- diabetes mellitus with vascular symptoms
- severe hypertension
- severe dyslipoproteinaemia
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1
• Known or suspected carcinoma of the breast
• Carcinoma of the endometrium or other known or suspected oestrogen-dependent neoplasia
• Abnormal liver function related to acute or chronic hepatocellular disease
• Hepatic adenomas or carcinomas
• Undiagnosed abnormal genital bleeding
• Concomitant use with the medicinal products containing ombitasvir/paritaprevir/ritonavir and
dasabuvir, medicinal products containing glecaprevir/pibrentasvir or
sofosbuvir/velpatasvir/voxilaprevir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) dasabuvir (HOS-110302) voxilaprevir (HOS-108930) ombitasvir (HOS-110300) velpatasvir (HOS-108929) ritonavir (HOS-084521) paritaprevir (HOS-110301)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-22T17:22:00Z · SHA-256 08ee5b4a9562d12725bc2847cb5a881102ab4ddbaaf7c1a2e28b65b78fd2ab5d · Passage 0b84b4ce379340aec479b3699d0b67d6f02d4b453bb9a5e3d40b02692d6515fc · Zeichen 895–2550 im Abschnitt
Wechselwirkungen · Evra
EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch · Abschnitt 4.5 · PDF-Seite 11
HOS-110304 · Präparat HOS-093363
Pharmacodynamic interactions
During clinical trials with patients treated for hepatitis C virus infections (HCV) with medicinal
products containing ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin,
transaminase (ALT) elevations higher than 5 times the upper limit of normal (ULN) occurred
significantly more frequently in women using ethinyl estradiol-containing medications such as
combined hormonal contraceptives (CHCs). Additionally, also in patients treated with
glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir, ALT elevations were observed in
women using ethinyl estradiol-containing medications such as CHCs (see section 4.3).
Therefore, EVRA-users must switch to an alternative method of contraception (e.g., progestagen-only
contraception or non-hormonal methods) prior to starting therapy with these combination drug
regimens. EVRA can be restarted 2 weeks following completion of treatment with these combination
drug regimens.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) ribavirin (HOS-088127) dasabuvir (HOS-110302) voxilaprevir (HOS-108930) ombitasvir (HOS-110300) velpatasvir (HOS-108929) ritonavir (HOS-084521) paritaprevir (HOS-110301)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-22T17:22:00Z · SHA-256 08ee5b4a9562d12725bc2847cb5a881102ab4ddbaaf7c1a2e28b65b78fd2ab5d · Passage a2c9d2476ababdf6aa70cd37d7f709e3b0de8b4455edc5193e41c8ca51311e4e · Zeichen 125–1104 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10–11
HOS-116802 · Präparat HOS-094481
10
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics neurotoxicity, QT prolongation) is unavoidable, consider
(e.g., telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, [see section 4.4]. the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors tacrolimus levels may occur, as tacrolimus the next day at a
(e.g., ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase > 5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with tacrolimus exposure may increase needed based on tacrolimus
and without dasabuvir), > 50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, The effect on tacrolimus blood first few days) and re-
ceritinib. concentrations may remain for evaluated on and after
Strong interactions have also several days after co-administration completion of the CYP3A4
been observed with the is completed. inhibitor. Upon completion,
macrolide antibiotic appropriate dose and dosing
erythromycin frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), prolongation) [see section 4.4]. A administration. Reduce
the macrolide antibiotics rapid increase in tacrolimus level tacrolimus dose if needed [see
(e.g., azithromycin), calcium may occur. section 4.2]. Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol,
lansoprazole, omeprazole,
the HCV antivirals
elbasvir/grazoprevir and
glecaprevir/pibrentasvir, the
CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib,
crizotinib and imatinib and
(Chinese) herbal remedies
containing extracts of
Schisandra sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 871fa2c72a31ddd6873cbb2f1b3b0dd9ad898b46eba141ac32a052a178cc3bc9 · Zeichen 3910–8415 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11
HOS-209742 · Präparat HOS-154375
10
Medicinal products which have effects on tacrolimus
Drug/Substance Class or Drug interaction effect Recommendations concerning co-
Name administration
Grapefruit or grapefruit juice May increase tacrolimus Avoid grapefruit or grapefruit
whole blood trough juice.
concentrations and increase
the risk of serious adverse
reactions (e.g., neurotoxicity,
QT prolongation) [see
section 4.4].
Ciclosporin May increase tacrolimus The simultaneous use of
whole blood trough ciclosporin and tacrolimus should
concentrations. In addition, be avoided [see section 4.4].
synergistic/additive
nephrotoxic effects can
occur.
Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus with
nephrotoxic or neurotoxic neurotoxic effects of drugs known to have nephrotoxic
effects: tacrolimus. effects should be avoided. When
aminoglycosides, gyrase co-administration cannot be
inhibitors, vancomycin, avoided, monitor renal function
sulfamethoxazole + and other side effects and adjust
trimethoprim, NSAIDs, tacrolimus dose if needed.
ganciclovir, acyclovir,
amphotericin B, ibuprofen
cidofovir, foscarnet
Strong CYP3A4 inhibitors: May increase tacrolimus It is recommended that
antifungal agents (e.g., whole blood trough concomitant use should be
ketoconazole, itraconazole, concentrations and increase avoided. If co-administration of a
posaconazole, voriconazole), the risk of serious adverse strong CYP3A4 inhibitor is
the macrolide antibiotics reactions (e.g., unavoidable, consider omitting
(e.g., telithromycin, nephrotoxicity, the dose of tacrolimus the day the
troleandomycin, neurotoxicity, QT strong CYP3A4 inhibitor is
clarithromycin, josamycin), prolongation) which requires initiated. Reinitiate tacrolimus the
HIV protease inhibitors (e.g., close monitoring [see next day at a reduced dose based
ritonavir, nelfinavir, section 4.4]. on tacrolimus blood
saquinavir), HCV protease Rapid and sharp increases in concentrations. Changes in both
inhibitors (e.g., telaprevir, tacrolimus levels may occur, tacrolimus dose and/or dosing
boceprevir, and the as early as within 1-3 days frequency should be
combination of ombitasvir after co-administration, individualized and adjusted as
and paritaprevir with despite immediate reduction needed based on tacrolimus
ritonavir, when used with and of tacrolimus dose. Overall trough concentrations, which
without dasabuvir), tacrolimus exposure may should be assessed at initiation,
nefazodone, the increase > 5 fold. When monitored frequently throughout
pharmacokinetic enhancer ritonavir combinations are (starting within the first few days)
cobicistat and the kinase co-administered, tacrolimus and re-evaluated on and after
inhibitors idelalisib, ceritinib. exposure may increase > 50 completion of the CYP3A4
Strong interactions have also fold. inhibitor. Upon completion,
been observed with the Nearly all patients may appropriate dose and dosing
macrolide antibiotic require a reduction in frequency of tacrolimus should be
erythromycin tacrolimus dose and guided by tacrolimus blood
temporary interruption of concentrations. Monitor renal
tacrolimus may also be function, ECG for QT
necessary. prolongation, and other side
effects closely.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ceritinib (HOS-086215) josamycin (HOS-113844) nefazodone (HOS-084519) nelfinavir (HOS-084520) ibuprofen (HOS-087884) protease (HOS-085623) amphotericin B (HOS-109312) trimethoprim (HOS-085184) ketoconazole (HOS-084513) cobicistat (HOS-088111) cidofovir (HOS-110482) grapefruit juice (HOS-088787) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) vancomycin (HOS-110486) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) ganciclovir (HOS-085194) paritaprevir (HOS-110301) acyclovir (HOS-088527) posaconazole (HOS-085622) idelalisib (HOS-116811)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 84292deca9b273b57aafc577a96618c8f1b67362b0e5f3bec58af5bfd6d618af · Zeichen 1995–6929 im Abschnitt
Wechselwirkungen · Zoely
Zoely 2.5 mg/1.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-123131 · Präparat HOS-095645
Direct acting antiviral agents (DAAs) and ethinylestradiol-containing medicinal products such as CHCs
During clinical trials with the HCV combination drug regimen ombitasvir/paritaprevir/ritonavir and
dasabuvir with or without ribavirin, ALT elevations greater than 5 times the upper limit of normal
(ULN) were significantly more frequent in women using ethinylestradiol-containing medicinal
products such as CHCs. Additionally, also in patients treated with glecaprevir/pibrentasvir or
sofosbuvir/velpatasvir/voxilaprevir, ALT elevations were observed in women using ethinylestradiol-
containing medications such as CHCs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) ribavirin (HOS-088127) dasabuvir (HOS-110302) voxilaprevir (HOS-108930) ombitasvir (HOS-110300) velpatasvir (HOS-108929) ritonavir (HOS-084521) paritaprevir (HOS-110301)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-19T01:25:00Z · SHA-256 dc49cf8021f816c4c7a796f72b78aa51d7e7cdb416565d60506c315b6ddcb3e2 · Passage 24ea5c47b8281fb85662d78cf5c0f9fcf46ea2b10396e0ac0ec89d7d3df9a088 · Zeichen 2975–3597 im Abschnitt
Wechselwirkungen · Zoely
Zoely 2.5 mg/1.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-123141 · Präparat HOS-095645
Direct acting antiviral agents (DAAs) and medicinal products containing oestrogens other than
ethinylestradiol, such as estradiol
Women using medicinal products containing oestrogens other than ethinylestradiol, such as estradiol,
and ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin had a rate of ALT
elevation similar to those not receiving any oestrogens; however, due to the limited number of women
taking these other oestrogens, caution is warranted for co-administration with the following
combination drug regimens: ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin;
glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) ribavirin (HOS-088127) dasabuvir (HOS-110302) voxilaprevir (HOS-108930) ombitasvir (HOS-110300) velpatasvir (HOS-108929) ritonavir (HOS-084521) paritaprevir (HOS-110301)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-19T01:25:00Z · SHA-256 dc49cf8021f816c4c7a796f72b78aa51d7e7cdb416565d60506c315b6ddcb3e2 · Passage 947c42be34de05e9f1fa6a962b97fee4c516c794ae509f0f584d04179575481e · Zeichen 3599–4304 im Abschnitt
Wechselwirkungen · Tacforius
Tacforius 0.5 mg prolonged-release hard capsules Tacforius 1 mg prolonged-release hard capsules Tacforius 3 mg prolonged-release hard capsules Tacforius 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 11–12
HOS-139158 · Präparat HOS-098290
11
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics (e.g., neurotoxicity, QT prolongation) is unavoidable, consider
telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, (see section 4.4). the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors (e.g., tacrolimus levels may occur, as tacrolimus the next day at a
ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase >5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with and tacrolimus exposure may increase needed based on tacrolimus
without dasabuvir), >50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, ceritinib. The effect on tacrolimus blood first few days) and re-
Strong interactions have also concentrations may remain for evaluated on and after
been observed with the several days after co-administration completion of the CYP3A4
macrolide antibiotic is completed. inhibitor. Upon completion,
erythromycin. appropriate dose and dosing
frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), the prolongation) (see section 4.4). A administration. Reduce
macrolide antibiotics (e.g., rapid increase in tacrolimus level tacrolimus dose if needed (see
azithromycin), calcium may occur. section 4.2). Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol, lansoprazole,
omeprazole, the HCV
antivirals elbasvir/grazoprevir
and glecaprevir/pibrentasvir,
the CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib, crizotinib
and imatinib and (Chinese)
herbal remedies containing
extracts of Schisandra
sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-08T17:10:00Z · SHA-256 bf71e479a3104e9d8dd9aede574f2baf87c2d76cd8cc9266ee2ef92ed475dc55 · Passage 68eefd97f11d29951c1cb7e82fce1c09e7dec9a4f694ee7101cde8ef1e7bf3ae · Zeichen 3968–8645 im Abschnitt
Wechselwirkungen · Lorviqua
Lorviqua 25 mg film-coated tablets Lorviqua 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-140205 · Präparat HOS-098468
Itraconazole, a strong inhibitor of CYP3A4/5, administered at oral doses of 200 mg once daily for
5 days, increased the mean lorlatinib AUCinf by 42% and Cmax by 24% of a single 100 mg oral dose of
lorlatinib in healthy volunteers. Concomitant administration of lorlatinib with strong CYP3A4/5
inhibitors (e.g. boceprevir, cobicistat, itraconazole, ketoconazole, posaconazole, troleandomycin,
voriconazole, ritonavir, paritaprevir in combination with ritonavir and ombitasvir and/or dasabuvir,
and ritonavir in combination with either elvitegravir, indinavir, lopinavir or tipranavir) may increase
lorlatinib plasma concentrations. Grapefruit products may also increase lorlatinib plasma
concentrations and should be avoided. An alternative concomitant medicinal product with less
potential to inhibit CYP3A4/5 should be considered. If a strong CYP3A4/5 inhibitor must be
concomitantly administered, a dose reduction of lorlatinib is recommended (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) ketoconazole (HOS-084513) cobicistat (HOS-088111) dasabuvir (HOS-110302) voriconazole (HOS-084524) itraconazole (HOS-084516) ombitasvir (HOS-110300) boceprevir (HOS-090617) troleandomycin (HOS-090575) ritonavir (HOS-084521) paritaprevir (HOS-110301) posaconazole (HOS-085622) elvitegravir (HOS-088110) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T10:16:00Z · SHA-256 e78bfe12c86e5d234c5c39cb88b4ddb1774142065643260a485f8cad944b4467 · Passage e8879edd76b5e755e2fe1c01adb047528d6e641219dc730314c408fa86169585 · Zeichen 1328–2292 im Abschnitt
Wechselwirkungen · Delstrigo
Delstrigo 100 mg/300 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-141202 · Präparat HOS-098610
Expected:
doravirine
Interaction not studied with
doravirine or
ombitasvir/paritaprevir/ doravirine/lamivudine/tenofovir
ritonavir and dasabuvir +/- disoproxil.
ritonavir No dose adjustment is required.
Expected:
doravirine
(Inhibition of CYP3A due to
ritonavir)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) dasabuvir (HOS-110302) ombitasvir (HOS-110300) ritonavir (HOS-084521) paritaprevir (HOS-110301)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T17:24:00Z · SHA-256 2c0deb57aeb6310e5014ea9012afd45619de92a00e9950f55a0cfcc2fdcdf2a8 · Passage bf32410ec6b3a70d38c1b8c9532f6afeb8f4eeb12a6aa906e56d026e23b5d1c1 · Zeichen 22357–22900 im Abschnitt
Wechselwirkungen · Delstrigo
Delstrigo 100 mg/300 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-141206 · Präparat HOS-098610
12
Recommendation concerning
Medicinal product by Effects on medicinal product levels co-administration with
therapeutic area geometric mean ratio (90 % CI)* doravirine/lamivudine/tenofovir
disoproxil
Interaction not studied with
doravirine or
doravirine/lamivudine/tenofovir
dasabuvir disoproxil. No dose adjustment is required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) dasabuvir (HOS-110302)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T17:24:00Z · SHA-256 2c0deb57aeb6310e5014ea9012afd45619de92a00e9950f55a0cfcc2fdcdf2a8 · Passage fb56344595141da44f9d7d240a868579b338d3feadf2dfe8e448114b80a130e5 · Zeichen 22953–23569 im Abschnitt
Wechselwirkungen · Pifeltro
Pifeltro 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-141264 · Präparat HOS-098618
GS-331007
AUC 1.03 (0.98, 1.09)
Cmax 1.03 (0.97, 1.09)
Interaction not studied.
sofosbuvir/velpatasvir No dose adjustment is required.
Expected:
doravirine
Interaction not studied.
sofosbuvir No dose adjustment is required.
Expected:
doravirine
Interaction not studied.
daclatasvir
No dose adjustment is required.
Expected:
↔ doravirine
Interaction not studied.
ombitasvir/
Expected:
paritaprevir/ritonavir and No dose adjustment is required.
doravirine
dasabuvir+/-ritonavir
(Inhibition of CYP3A due to
ritonavir)
Interaction not studied.
dasabuvir Expected: No dose adjustment is required.
doravirine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daclatasvir (HOS-119742) sofosbuvir (HOS-108928) dasabuvir (HOS-110302) ombitasvir (HOS-110300) velpatasvir (HOS-108929) ritonavir (HOS-084521) paritaprevir (HOS-110301)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T08:41:00Z · SHA-256 e669d0797aaecb09c38b8d2518d46b353834062d76517638eed9a33ed2fd94be · Passage 7a6aff4b5ae442d9eab5762e15c9e3ab5f8d6fd0a2549b2c092f26202ede10fe · Zeichen 14152–15538 im Abschnitt
Wechselwirkungen · Drovelis
Drovelis 3 mg/14.2 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-146475 · Präparat HOS-099526
Concomitant use with the HCV medicinal products containing ombitasvir/paritaprevir/ritonavir and
dasabuvir, with or without ribavirin, may increase the risk of ALT elevations in women using
ethinylestradiol containing medicinal products such as CHCs (see section 4.4). Women using
medicinal products containing oestrogens other than ethinylestradiol, had a rate of ALT elevation
similar to those not receiving any oestrogens; however, due to the limited number of women taking
these other oestrogens, caution is warranted for co-administration with the combination therapeutic
regimen ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin and also the regimen
with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) ribavirin (HOS-088127) dasabuvir (HOS-110302) voxilaprevir (HOS-108930) ombitasvir (HOS-110300) velpatasvir (HOS-108929) ritonavir (HOS-084521) paritaprevir (HOS-110301)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-10T12:55:00Z · SHA-256 69e66a6243c1d9a3de0a88ac010cbabd1405527c8e76c9065b3d238f26ce840f · Passage c92123817fa43e381ccd32c0c58e6b45274765dc7c131039359791d0adbbf99d · Zeichen 4095–4862 im Abschnitt
Wechselwirkungen · Retsevmo
Retsevmo 40 mg hard capsules Retsevmo 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 9–10
HOS-146806 · Präparat HOS-099572
9
amodiaquine, cerivastatin, enzalutamide, paclitaxel, repaglinide, torasemide, sorafenib, rosiglitazone,
buprenorphine, selexipag, dasabuvir and montelukast), should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cerivastatin (HOS-146808) amodiaquine (HOS-146807) montelukast (HOS-122836) rosiglitazone (HOS-089664) buprenorphine (HOS-086193) dasabuvir (HOS-110302) paclitaxel (HOS-087959) sorafenib (HOS-115745) enzalutamide (HOS-116829) repaglinide (HOS-086935) selexipag (HOS-131246)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T11:29:00Z · SHA-256 ea39918a3fb80726ed18974b1aa44d085db9e48e01020d5741da30903ff4eadc · Passage 406e79a4657b8fd89bcf9212ecf31d6ce4d2117b275c8de020b28bc35f6e9bfa · Zeichen 2059–2238 im Abschnitt
Wechselwirkungen · Retsevmo
Retsevmo 40 mg film-coated tablets Retsevmo 80 mg film-coated tablets Retsevmo 120 mg film-coated tablets Retsevmo 160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-146886 · Präparat HOS-099572
Sensitive CYP2C8 substrates
Selpercatinib increased the Cmax and AUC of repaglinide (a substrate of CYP2C8) by approximately
91% and 188% respectively. Therefore, co-administration with sensitive CYP2C8 substrates (e.g.,
amodiaquine, cerivastatin, enzalutamide, paclitaxel, repaglinide, torasemide, sorafenib, rosiglitazone,
buprenorphine, selexipag, dasabuvir and montelukast), should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cerivastatin (HOS-146808) amodiaquine (HOS-146807) montelukast (HOS-122836) rosiglitazone (HOS-089664) buprenorphine (HOS-086193) dasabuvir (HOS-110302) paclitaxel (HOS-087959) sorafenib (HOS-115745) enzalutamide (HOS-116829) repaglinide (HOS-086935) selexipag (HOS-131246)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T11:29:00Z · SHA-256 ea39918a3fb80726ed18974b1aa44d085db9e48e01020d5741da30903ff4eadc · Passage ea585bf1f3009cba45b81586de5971f4d723097568353585019a425088253d03 · Zeichen 1785–2182 im Abschnitt
Wechselwirkungen · Jaypirca
Jaypirca 50 mg film-coated tablets Jaypirca 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-149909 · Präparat HOS-100173
CYP2C8 substrates
Pirtobrutinib is a moderate inhibitor of CYP2C8. Pirtobrutinib increased the AUC and Cmax of
repaglinide (a substrate of CYP2C8) by 130 % and 98 %, respectively. Therefore, since pirtobrutinib
can increase the plasma concentrations of CYP2C8 substrates, caution is advised when
co-administering with CYP2C8 substrates (e.g. repaglinide, dasabuvir, selexipag, rosiglitazone,
pioglitazone, and montelukast).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): montelukast (HOS-122836) rosiglitazone (HOS-089664) dasabuvir (HOS-110302) pioglitazone (HOS-089663) repaglinide (HOS-086935) selexipag (HOS-131246)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-15T09:42:02Z · SHA-256 ac51358255b0e15966ab90f4c5f817ad50f84358de56be652a1c06ce9fa9a7c6 · Passage 5d90d59981f30376d23b297966141888be8f166b96328301c892e8942d5d9c3d · Zeichen 1132–1555 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.